IBRX analyst estimates
ImmunityBio (IBRX) analyst ratings, the average price target and its range, and every firm's latest call.
IBRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 14, 2026 | Piper Sandler | ImmunityBio price target raised to $16 from $12 at Piper Sandler | $16.00 |
| Oct 14, 2026 | Jefferies | ImmunityBio price target raised to $14 from $12 at Jefferies | $14.00 |
| May 8, 2026 | BTIG | ImmunityBio price target lowered to $12 from $13 at BTIG | $12.00 |
| Mar 4, 2026 | Piper Sandler | Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler | $12.00 |
| Feb 23, 2026 | H.C. Wainwright | ImmunityBio price target raised to $15 from $10 at H.C. Wainwright | $15.00 |
| Jan 20, 2026 | Piper Sandler | ImmunityBio price target raised to $7 from $5 at Piper Sandler | $7.00 |
| Jan 10, 2025 | BTIG | ImmunityBio initiated with a Buy at BTIG | $6.00 |
| Aug 3, 2022 | Jefferies | Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline | $8.00 |
- 5 firms rate IBRX: 5 buy, 0 hold, 0 sell.
- The average price target is $14.00 from 3 analysts, from $12.00 to $16.00.
Updated 2026-11-07 11:52 UTC